Objective: To investigate whether seminatural cycle is a reasonable management for ovarian aging patients. Design: Prospective study. Setting: ART Unit, Clamart, France. Patient(s): Seventy-five women, 158 cycles. Int...Objective: To investigate whether seminatural cycle is a reasonable management for ovarian aging patients. Design: Prospective study. Setting: ART Unit, Clamart, France. Patient(s): Seventy-five women, 158 cycles. Intervention(s): Infertile women who presented with ovarian aging (defined as low ovarian reserve and characterized by cycle day 3 high FSH, high E2, and/or low inhibin B and/or previous cycle cancellations due to poor ovarian response to COH) were studied. Patients were offered up to three cycles. Treatment was scheduled as follows. From cycle day 8 onward the selection of the dominant follicle was monitored by ultrasound and hormonal measurements. When the dominant follicle appeared, patients received GnRH antagonist and, thereafter, hMG to support further follicular development. Main Outcome Measure(s): Implantation rate and clinical pregnancy. Result(s): Twenty-eight of 158 cycles were cancelled (17.7%). Oocyte pickups were performed in 119 (75.3%) cycles, 91 (57.6%) mature oocytes were retrieved, and 67 (42.4%) embryos transferred. Nineteen clinical pregnancies were obtained; the cumulative pregnancy rate per patient, after 3 cycles, was 35.2%. Conclusion(s): Use of a seminatural cycle is a reasonable management for patients with ovarian aging who have ovulatory menstrual cycles. It achieves a high implantation rate (28.3%).展开更多
文摘Objective: To investigate whether seminatural cycle is a reasonable management for ovarian aging patients. Design: Prospective study. Setting: ART Unit, Clamart, France. Patient(s): Seventy-five women, 158 cycles. Intervention(s): Infertile women who presented with ovarian aging (defined as low ovarian reserve and characterized by cycle day 3 high FSH, high E2, and/or low inhibin B and/or previous cycle cancellations due to poor ovarian response to COH) were studied. Patients were offered up to three cycles. Treatment was scheduled as follows. From cycle day 8 onward the selection of the dominant follicle was monitored by ultrasound and hormonal measurements. When the dominant follicle appeared, patients received GnRH antagonist and, thereafter, hMG to support further follicular development. Main Outcome Measure(s): Implantation rate and clinical pregnancy. Result(s): Twenty-eight of 158 cycles were cancelled (17.7%). Oocyte pickups were performed in 119 (75.3%) cycles, 91 (57.6%) mature oocytes were retrieved, and 67 (42.4%) embryos transferred. Nineteen clinical pregnancies were obtained; the cumulative pregnancy rate per patient, after 3 cycles, was 35.2%. Conclusion(s): Use of a seminatural cycle is a reasonable management for patients with ovarian aging who have ovulatory menstrual cycles. It achieves a high implantation rate (28.3%).
